We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Immunity Proteins Linked to Cancer

By LabMedica International staff writers
Posted on 01 Aug 2013
A set of proteins involved in immunity, which are supposed to defend the body, have the adverse effect of creating a large number of mutations in DNA.

These genetic mutations produce tumors in the human body, especially when these proteins transform, and can account for the majority of variations in some very aggressive cancers.

Image: Crystallography of Apolipoprotein B messenger RNA-editing enzyme (Image courtesy of Justin Steinfeld).
Image: Crystallography of Apolipoprotein B messenger RNA-editing enzyme (Image courtesy of Justin Steinfeld).

Scientists from the US National Institute of Environmental Health Sciences (Durham, NC, USA) examined 954,247 mutations within 2,680 cancer samples. Almost 70% of mutations resulted from the apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like cytidine deaminases (APOBEC) protein in some tumors. The investigators found that APOBEC mutations can outnumber all other mutations in some cancers, accounting for over two-thirds in some bladder, cervical, breast, head and neck, and lung tumors.

The APOBEC proteins are known to be of benefit, shutting down viruses that attack the body, but the scientists were surprised to find that they are also a detriment, mutating DNA. They found 498 total clusters in the 2,680 sequenced exomes from 14 different cancer types. In total, 218 cytosine- or guanine-coordinated clusters were identified, occurring in every cancer type analyzed except acute myeloid leukemia. Several cancer types showed high levels of the APOBEC mutation pattern as well as a wide variation among individual samples, which could reflect different biological pathways leading to carcinogenesis and the greatest range of variation was observed in breast cancer.

Dmitry A. Gordenin, PhD, a senior scientist and corresponding author of the study said, “The presence of APOBEC clusters in the genome of tumor cells indicates that APOBEC enzymes could also have caused many mutations across the genome.” His coauthor, Steven A. Roberts, added, “We hope that determining the environmental link to these mutations will lead to viable cancer prevention strategies.” The study was published on July 14, 2013, in the journal Nature Genetics.

Related Links:

US National Institute of Environmental Health Sciences



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automated Staining Unit
RAL Stainer

Latest Pathology News

AI-Based Model Predicts Kidney Cancer Therapy Response
31 Jul 2013  |   Pathology

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
31 Jul 2013  |   Pathology

World’s First AI Model for Thyroid Cancer Diagnosis Achieves Over 90% Accuracy
31 Jul 2013  |   Pathology